Estrogen Receptor Beta 5 antibody | 5/25
Immunohistochemical studies have revealed a ubiquitous expression of ERB5 in normal colorectal tissue, and to be present in all primary colorectal carcinomas studied (Wong, N. et al. 2005).
The detection of estrogen (ER) and progesterone (PR) receptors using immunohistochemical staining of formal fixed paraffin embedded (FFPE) tissue, has gradually replaced ligand binding assays (LBA), to become the most common method for the determination of the ER/PR status of breast tumors. Approximately 75% to 80% of breast tumors have estrogen and/or progesterone receptors, and the presence of these receptors helps determine both the patient’s prognosis and the effectiveness of hormonal therapy transcription (Shaaban et al. 2008, Collins et al. 2009).
- Target Species
- Product Form
- Purified IgG - liquid
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.1% Sodium Azide (NaN3)
- Tuberculin conjugated synthetic peptide LLSHVRHARYAP derived from the C-terminus of human ERB5.
- Approx. Protein Concentrations
- IgG concentration 1.0mg/ml
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
- 18 months from date of despatch.
- Q92731 Related reagents
- Entrez Gene
- ESR2 Related reagents
- For research purposes only
Applications of Estrogen Receptor Beta 5 antibody
|Application Name||Verified||Min Dilution||Max Dilution|
|Immunohistology - Paraffin 1|
- 1This product requires antigen retrieval using heat treatment prior to staining of paraffin sections.Sodium citrate buffer pH 6.0 is recommended for this purpose.
- Histology Positive Control Tissue
- Normal colon or colon carcinoma
Secondary Antibodies Available
Product Specific References
References for Estrogen Receptor Beta 5 antibody
Wong, N.A. et al. (2005) ERbeta isoform expression in colorectal carcinoma: an in vivo and in vitro study of clinicopathological and molecular correlates.
J Pathol. 207 (1): 53-60.
Shaaban, A.M. et al. (2008) Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients.
Clin Cancer Res. 14 (16): 5228-35.
Collins, F. et al. (2009) Expression of oestrogen receptors, ERalpha, ERbeta, and ERbeta variants, in endometrial cancers and evidence that prostaglandin F may play a role in regulating expression of ERalpha.
BMC Cancer. 9: 330.
Ciucci, A. et al. (2014) Gender effect in experimental models of human medulloblastoma: does the estrogen receptor β signaling play a role?
PLoS One. 9 (7): e101623.
Zannoni, G.F. et al. (2016) Sexual dimorphism in medulloblastoma features.
Histopathology. 68 (4): 541-8.
Li, S.Y. et al. (2015) Cytoplasm estrogen receptor β5 as an improved prognostic factor in thymoma and thymic carcinoma progression.
Oncol Lett. 10 (4): 2341-6.
Ciucci, A. et al. (2018) Estrogen receptor β: Potential target for therapy in adult granulosa cell tumors?
Gynecol Oncol. 150 (1): 158-65.